menu
    • menu
    [{"orgOrder":0,"company":"MegaPro Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"MegaPro Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MegaPro Biomedical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MegaPro Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"MegaPro Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Epinephrine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"MegaPro Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MegaPro Biomedical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MegaPro Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"MegaPro Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"TAIWAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MPB-1514","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase II","graph3":"MegaPro Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MegaPro Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MegaPro Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"MegaPro Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"MPB-1523","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"MegaPro Biomedical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MegaPro Biomedical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MegaPro Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"MegaPro Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MPB-1734","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MegaPro Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MegaPro Biomedical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"MegaPro Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"MegaPro Biomedical","sponsor":"National Taiwan University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MPB-2043","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"MegaPro Biomedical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MegaPro Biomedical \/ National Taiwan University Hospital","highestDevelopmentStatusID":"6","companyTruncated":"MegaPro Biomedical \/ National Taiwan University Hospital"}]

    Find Clinical Drug Pipeline Developments & Deals by MegaPro Biomedical

    Menu

    MegaPro Biomedical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MegaPro Biomedical

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MegaPro Biomedical

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MPB-2043

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : National Taiwan University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas

                            Details : MPB-2043 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Squamous Cell Carcinoma of Head and Neck.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 06, 2024

                            Lead Product(s) : MPB-2043

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : National Taiwan University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MegaPro Biomedical

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MegaPro Biomedical

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MPB-1734

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors

                            Details : MPB-1734 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 25, 2020

                            Lead Product(s) : MPB-1734

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MegaPro Biomedical

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MegaPro Biomedical

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MPB-1514

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Single Ascending Study of IOP Injection in Patients With Iron Deficient Anemia

                            Details : MPB-1514 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia, Iron-Deficiency.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 02, 2018

                            Lead Product(s) : MPB-1514

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MegaPro Biomedical

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MegaPro Biomedical

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MPB-1523

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma

                            Details : MPB-1523 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 23, 2018

                            Lead Product(s) : MPB-1523

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MegaPro Biomedical

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MegaPro Biomedical

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase Ib, Administration the IOP Injection for MRI Contrast Agent in Healthy Subjects

                            Details : IOP is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 16, 2018

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MegaPro Biomedical

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MegaPro Biomedical

                            Taiwan arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I , MTD, Pharmacokinetic, Safety/Tolerability, Efficacy of IOP Injection for MRI in Healthy Subjects

                            Details : IOP is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 20, 2016

                            Lead Product(s) : Epinephrine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth